Lauren Silvernail - CFO & CBO, Revance Therapeutics, Inc

As of May 24, 2018


Lauren Silvernail Net Worth

  • Net worth is estimated to be at least $4.98M
  • Owns at least 65,497 units of Revance Therapeutics, Inc stock
  • Sold an estimated value of $2.58M in the last 4 years at Revance Therapeutics, Inc

Lauren Silvernail Trading

  • Largest purchase of shares was 25,867 units , worth over $225.04K on March 15, 2018
  • Largest sale of shares was 27,019 units , worth over $928.87K on March 15, 2018
  • In total has made about 26 transactions over 4 years
  • Usually trades in May, with the busiest year in 2018 and 2017
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Lauren Silvernail Mailing Address

  • Mailing address is 15279 Alton Parkway Suite #100 Irvine CA 92618 CA

Revance Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark J. Foley 2020 $650,000 $ $7,794,350 $ $328,331 $8,255 $8,780,936
Mark J. Foley 2019 $189,764 $150,000 $11,728,370 $5,112,573 $ $9,723 $17,190,430
Tobin C. Schilke 2020 $421,375 $ $1,131,345 $1,273,662 $143,186 $11,531 $2,981,099
Tobin C. Schilke 2019 $407,126 $25,000 $86,150 $299,781 $178,123 $11,078 $1,007,258
Tobin C. Schilke 2018 $64,644 $25,000 $449,280 $1,434,350 $ $233 $1,973,507
Abhay Joshi, Ph.D. 2020 $514,608 $ $1,405,850 $1,913,759 $213,726 $11,731 $4,059,674
Abhay Joshi, Ph.D. 2019 $485,479 $ $271,373 $939,314 $204,211 $9,520 $1,909,897
Abhay Joshi, Ph.D. 2018 $469,062 $ $342,513 $1,192,465 $232,186 $9,210 $2,245,436
Dustin Sjuts 2020 $415,000 $ $1,294,250 $1,306,320 $141,020 $66,242 $3,222,832
Dustin Sjuts 2019 $378,333 $50,000 $43,075 $99,927 $183,902 $45,786 $801,023
Dwight Moxie 2020 $370,104 $125,000 $1,309,383 $2,579,240 $125,426 $10,356 $4,519,508
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000089/rvncfy20proxystatementdef1.htm

Revance Therapeutics, Inc Insider Trading

  • The most recent transaction was 14,313 units sold on August 17, 2021 by Aubrey Rankin worth over $375.43K
  • In the last 7 years, insiders at Revance Therapeutics, Inc sold an estimated value of $28.34M and bought an estimated value of $7.54M
  • The most active traders are Daniel Browne, CEO and President,  Curtis Ruegg, EVP,  and Lauren Silvernail, CFO & CBO
  • Insider trading is most common in May, with the busiest year in 2015 and 2018

Revance Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1